NasdaqCM - Nasdaq Real Time Price USD

BioNexus Gene Lab Corp. (BGLC)

3.2200

-0.0600

(-1.83%)

At close: June 5 at 4:00:00 PM EDT

BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness

KUALA LUMPUR, Malaysia, April 30, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC), a biotechnology company specializing in precision diagnostics and specialty chemical solutions, today announced that it has received official notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming the Company has regained full compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. This important milestone reaffirms the Company’s standing

GlobeNewswire last month

BGLC
-1.83%
BioNexus Gene Lab Corp. Files 2024 Annual Report Highlighting Strategic Innovation, Operational Resilience, and Growth Trajectory

KUALA LUMPUR, Malaysia, April 15, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a diversified biotechnology and specialty materials group headquartered in Malaysia and incorporated in Wyoming, today announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission. The Company’s 2024 report showcases a year of strategic realignment, technological advancement, and en

GlobeNewswire last month

BGLC
-1.83%
Bionexus Gene Lab enters partnership with ML Tech

BioNexus Gene Lab (BGLC) announced a strategic partnership with ML Tech to optimize the BGLC’s Ethereum-based growth strategies. Through this partnership, BGLC plans to leverage ML Tech’s digital asset trading infrastructure to grow its Ethereum holdings. ML Tech, known for its institutional-grade trading strategies and advanced quantitative models, will provide BioNexus with tailored investment solutions designed to maximize returns while maintaining stringent risk management protocols. Publish

TipRanks 2 months ago

BGLC
-1.83%
BioNexus Gene Lab Leads Our Top 3 US Penny Stocks

The U.S. stock market has been on a notable upswing, with the S&P 500 and Nasdaq reaching record highs following positive employment data that bolstered confidence in economic strength. For investors exploring beyond the well-known giants, penny stocks—typically smaller or newer companies—can offer intriguing opportunities despite their somewhat antiquated name. These stocks can provide surprising value when based on solid financials, and we will explore three examples that showcase potential...

Simply Wall St. 5 months ago

RFL

NEPH

BGLC
-1.83%
BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd.

BGLC and Protech Representatives Agreement Handover Mr. Lai representing BioNexus Gene Lab Corp. (BGLC) and Mr. Wong representing Protech Builders Sdn. Bhd. (Protech) during the handover of agreements KUALA LUMPUR, Malaysia, Sept. 25, 2024 (GLOBE NEWSWIRE) -- MRNA Scientific Sdn. Bhd. ("MRNA"), a subsidiary of BioNexus Gene Lab Corp. (Nasdaq: BGLC, the “Company”), and Protech Builders Sdn. Bhd. ("Protech"), a leading mechanical and electrical engineering construction firm in Malaysia, are please

GlobeNewswire 8 months ago

BGLC
-1.83%
BioNexus Gene Lab Corp. Signs Strategic Outsourcing Agreement with VITARRAY Global Pte. Ltd.

KUALA LUMPUR, Malaysia, Sept. 14, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC, the “Company”), an emerging biotechnology company focused on innovative healthcare solutions, is pleased to announce that its wholly owned subsidiary, MRNA Scientific Sdn. Bhd. (“MRNA Scientific”), has entered into a strategic outsourcing agreement with VITARRAY Global Pte. Ltd. (“Vitarray”), an exempted private company incorporated in Singapore. This agreement focuses on the provision of mRNA dynam

GlobeNewswire 8 months ago

BGLC
-1.83%
BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions

BGLC CEO and representative of Shenzhen Rongguang Health MOU Signing Ceremony BGLC CEO and representative of Shenzhen Rongguang Health MOU Signing Ceremony KUALA LUMPUR, Malaysia, Sept. 13, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC, the “Company”), an emerging biotechnology company focused on innovative healthcare solutions, is pleased to announce the signing of a strategic partnership Memorandum of Understanding (MOU) with Shenzhen Rongguang Health Group, a major healthcare

GlobeNewswire 8 months ago

BGLC
-1.83%
BioNexus Gene Lab Corp Announces New Business Developments for Subsidiary Chemrex with Investment in High-Quality Color Paste Production

KUALA LUMPUR, Malaysia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp (Nasdaq: BGLC, the “Company”), an emerging Biotech & Chemicals company, is pleased to announce that its subsidiary, Chemrex Corporation Sdn. Bhd. (Chemrex), has invested approximately RM 2 million (approx. USD $450,000) to begin the production of fine-quality color paste (non-drying type) specifically designed for composite industrial customers. The new production facility will commence operations in late September

GlobeNewswire 8 months ago

BGLC
-1.83%
BioNexus Gene Lab Corp. Announces Successful Securities Commission of Malaysia (MyCIF) Co-Investment in Ascension Innovation Sdn Bhd

KUALA LUMPUR, Malaysia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC), an emerging leader in genomic diagnostics and personalized medicine, is pleased to announce the successful co-investment by the Securities Commission of Malaysia under its Malaysia Co-Investment Fund (MyCIF), into Ascension Innovation Sdn Bhd (AISB). This co-investment, alongside BGLC's recent investment, the first under its Environmental & Social Impact (ESI) Scheme shows confidence in the strategi

GlobeNewswire 9 months ago

BGLC
-1.83%
BioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd

KUALA LUMPUR, Malaysia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC), an emerging leader in genomic diagnostics and health technology, today announced the successful closing of its RM 1 million (Approx. USD228k) investment in Ascension Innovation Sdn Bhd (AISB), a pioneering Malaysian healthcare technology firm. This strategic investment, executed through BGLC’s wholly-owned subsidiary, MRNA Scientific Sdn Bhd, solidifies BGLC’s commitment to advancing AI-driven healt

GlobeNewswire 9 months ago

BGLC
-1.83%
BioNexus Gene Lab Second Quarter 2024 Earnings: US$0.005 loss per share (vs US$0.018 loss in 2Q 2023)

BioNexus Gene Lab ( NASDAQ:BGLC ) Second Quarter 2024 Results Key Financial Results Revenue: US$11.9k (down 100% from...

Simply Wall St. 9 months ago

BGLC
-1.83%

Performance Overview

Return	BGLC	S&P 500 (^GSPC)
YTD	+15.00%	+0.98%
1-Year	-35.60%	+10.93%
3-Year	-97.87%	+44.56%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioNexus Gene Lab Corp. (BGLC)

BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness

BioNexus Gene Lab Corp. Files 2024 Annual Report Highlighting Strategic Innovation, Operational Resilience, and Growth Trajectory

Bionexus Gene Lab enters partnership with ML Tech

BioNexus Gene Lab Leads Our Top 3 US Penny Stocks

BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd.

BioNexus Gene Lab Corp. Signs Strategic Outsourcing Agreement with VITARRAY Global Pte. Ltd.

BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions

BioNexus Gene Lab Corp Announces New Business Developments for Subsidiary Chemrex with Investment in High-Quality Color Paste Production

BioNexus Gene Lab Corp. Announces Successful Securities Commission of Malaysia (MyCIF) Co-Investment in Ascension Innovation Sdn Bhd

BioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd

BioNexus Gene Lab Second Quarter 2024 Earnings: US$0.005 loss per share (vs US$0.018 loss in 2Q 2023)

Performance Overview